GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » Beneish M-Score

Cabio Biotech (Wuhan) Co (SHSE:688089) Beneish M-Score : -2.05 (As of Jun. 03, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cabio Biotech (Wuhan) Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.05 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Cabio Biotech (Wuhan) Co's Beneish M-Score or its related term are showing as below:

SHSE:688089' s Beneish M-Score Range Over the Past 10 Years
Min: -3.17   Med: -2.37   Max: 0.75
Current: -2.05

During the past 11 years, the highest Beneish M-Score of Cabio Biotech (Wuhan) Co was 0.75. The lowest was -3.17. And the median was -2.37.


Cabio Biotech (Wuhan) Co Beneish M-Score Historical Data

The historical data trend for Cabio Biotech (Wuhan) Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cabio Biotech (Wuhan) Co Beneish M-Score Chart

Cabio Biotech (Wuhan) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 -1.80 -1.86 -3.17 -2.03

Cabio Biotech (Wuhan) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.84 -2.37 -2.40 -2.03 -2.05

Competitive Comparison of Cabio Biotech (Wuhan) Co's Beneish M-Score

For the Biotechnology subindustry, Cabio Biotech (Wuhan) Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cabio Biotech (Wuhan) Co's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cabio Biotech (Wuhan) Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cabio Biotech (Wuhan) Co's Beneish M-Score falls into.



Cabio Biotech (Wuhan) Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cabio Biotech (Wuhan) Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2901+0.528 * 0.9491+0.404 * 1.0502+0.892 * 1.0615+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.738+4.679 * -0.010006-0.327 * 0.6395
=-2.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ¥287.9 Mil.
Revenue was 117.02 + 118.975 + 126.068 + 110.999 = ¥473.1 Mil.
Gross Profit was 47.387 + 54.406 + 52.178 + 47.908 = ¥201.9 Mil.
Total Current Assets was ¥695.3 Mil.
Total Assets was ¥1,617.2 Mil.
Property, Plant and Equipment(Net PPE) was ¥666.4 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0.0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥38.8 Mil.
Total Current Liabilities was ¥95.1 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0.7 Mil.
Net Income was 24.313 + 30.96 + 25.567 + 20.54 = ¥101.4 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0.0 Mil.
Cash Flow from Operations was 43.387 + 43.715 + 5.225 + 25.235 = ¥117.6 Mil.
Total Receivables was ¥210.2 Mil.
Revenue was 87.762 + 160.18 + 102.096 + 95.606 = ¥445.6 Mil.
Gross Profit was 33.668 + 60.02 + 44.833 + 41.973 = ¥180.5 Mil.
Total Current Assets was ¥834.8 Mil.
Total Assets was ¥1,592.1 Mil.
Property, Plant and Equipment(Net PPE) was ¥517.8 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0.0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥49.5 Mil.
Total Current Liabilities was ¥144.8 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2.5 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(287.912 / 473.062) / (210.242 / 445.644)
=0.608614 / 0.471771
=1.2901

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(180.494 / 445.644) / (201.879 / 473.062)
=0.405018 / 0.42675
=0.9491

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (695.345 + 666.383) / 1617.239) / (1 - (834.777 + 517.809) / 1592.11)
=0.157992 / 0.150444
=1.0502

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=473.062 / 445.644
=1.0615

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 517.809)) / (0 / (0 + 666.383))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(38.799 / 473.062) / (49.527 / 445.644)
=0.082017 / 0.111136
=0.738

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.662 + 95.051) / 1617.239) / ((2.508 + 144.843) / 1592.11)
=0.059183 / 0.092551
=0.6395

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(101.38 - 0 - 117.562) / 1617.239
=-0.010006

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cabio Biotech (Wuhan) Co has a M-score of -2.05 suggests that the company is unlikely to be a manipulator.


Cabio Biotech (Wuhan) Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Cabio Biotech (Wuhan) Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cabio Biotech (Wuhan) Co (SHSE:688089) Business Description

Traded in Other Exchanges
N/A
Address
No. 999, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, CHN, 430073
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
Executives
Shang Yun Core technical personnel
Wang Hua Biao Directors, senior managers
Geng An Feng senior management
Du Bin Director
Yi Hua Rong senior management
Ma Tao senior management
Li Xiang Yu senior management
Wu Yu Jun Supervisors
Xiao Min senior management
Wang Zhi Ming senior management
Lu Shu Huan Core technical personnel
Yi De Wei Director

Cabio Biotech (Wuhan) Co (SHSE:688089) Headlines

No Headlines